These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 5508247)

  • 1. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity.
    Wu TT; Kabat EA
    J Exp Med; 1970 Aug; 132(2):211-50. PubMed ID: 5508247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of invariant residues in the variable and constant regions of human K, human L, and mouse K Bence-Jones proteins.
    Kabat EA
    Proc Natl Acad Sci U S A; 1967 Jul; 58(1):229-33. PubMed ID: 5231603
    [No Abstract]   [Full Text] [Related]  

  • 3. Some correlations between specificity and sequence of the first complementarity-determining segments of human kappa light chains.
    Kabat EA; Wu TT; Bilofsky H
    Proc Natl Acad Sci U S A; 1976 Dec; 73(12):4471-3. PubMed ID: 826908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary structure of the variable part of an amyloidogenic Bence-Jones Protein (Mev.). An unusual insertion in the third hypervariable region of a human kappa-immunoglobulin light chain.
    Eulitz M; Linke RP
    Hoppe Seylers Z Physiol Chem; 1982 Nov; 363(11):1347-58. PubMed ID: 6816713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rabbit antibody with light chain having an N-terminal valyl residue.
    Seon BK; Roholt OA; Pressman D
    Immunochemistry; 1971 Jul; 8(7):585-92. PubMed ID: 4108805
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel human light chain V kappa segment: serologic and structural analyses of the kappa III-like Bence Jones protein and IgG kappa light chain REE.
    Prelli F; Tummolo D; Solomon A; Frangione B
    J Immunol; 1986 Jun; 136(11):4169-73. PubMed ID: 2422275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pillars article: an analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med. 1970. 132: 211-250.
    Wu TT; Kabat EA
    J Immunol; 2008 Jun; 180(11):7057-96. PubMed ID: 18490705
    [No Abstract]   [Full Text] [Related]  

  • 8. Study of the frequency of kappa and lambda light chains in 347 sera containing a monoclonal IgG, IgA, IgD, or Bence-Jones protein.
    Fine JM
    Rev Eur Etud Clin Biol; 1970 Feb; 15(2):199-202. PubMed ID: 4192027
    [No Abstract]   [Full Text] [Related]  

  • 9. Amino acid sequence of an amyloidogenic Bence Jones protein in myeloma-associated systemic amyloidosis.
    Tonoike H; Kametani F; Hoshi A; Shinoda T; Isobe T
    FEBS Lett; 1985 Jun; 185(1):139-41. PubMed ID: 3922791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda).
    Solomon A; Frangione B; Franklin EC
    J Clin Invest; 1982 Aug; 70(2):453-60. PubMed ID: 6808027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiotypical identity of IgG myeloma protein with monoclonal IgM, Bence Jones protein, and Fv derived from one patient.
    Miyagawa N; Morita K; Azuma T
    Microbiol Immunol; 1990; 34(9):787-94. PubMed ID: 1704478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human kappa Bence Jones protein (subgroup I) showing new amino acid substitutions.
    Matthews JB; Jefferis R
    Immunochemistry; 1977; 14(11-12):793-7. PubMed ID: 413784
    [No Abstract]   [Full Text] [Related]  

  • 13. The V region sequence of lambda Bence-Jones protein Wh: evidence for separate germ-line sets within lambda-subgroups.
    Kiefer CR; Patton HM; McGuire BS; Garver FA
    J Immunol; 1980 Jan; 124(1):301-6. PubMed ID: 7350229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Myeloma as a tool for elucidation of the mechanism of antibody diversity].
    Laskov R
    Harefuah; 1972 Jan; 82(2):78-85. PubMed ID: 4565408
    [No Abstract]   [Full Text] [Related]  

  • 15. Carboxy-terminal structure of the chain of human IgA myeloma proteins.
    Prahl JW; Abel CA; Grey HM
    Biochemistry; 1971 May; 10(10):1808-12. PubMed ID: 4998234
    [No Abstract]   [Full Text] [Related]  

  • 16. Primary structure of the variable region of a human lambda VI light chain: Bence Jones protein SUT.
    Frangione B; Moloshok T; Solomon A
    J Immunol; 1983 Nov; 131(5):2490-3. PubMed ID: 6415173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel arrangement of immunoglobulin variable domains: X-ray crystallographic analysis of the lambda-chain dimer Bence-Jones protein Loc.
    Chang CH; Short MT; Westholm FA; Stevens FJ; Wang BC; Furey W; Solomon A; Schiffer M
    Biochemistry; 1985 Aug; 24(18):4890-7. PubMed ID: 3935155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma with serum IgM kappa and Bence Jones lambda biclonal gammopathy.
    Graziani MS; Lippi U
    Clin Chem; 1986 Dec; 32(12):2220-1. PubMed ID: 3096615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains.
    Kabat EA; Wu TT
    Ann N Y Acad Sci; 1971 Dec; 190():382-93. PubMed ID: 5290024
    [No Abstract]   [Full Text] [Related]  

  • 20. Unique features of the variable regions of Bence Jones proteins and their possible relation to antibody complementarity.
    Kabat EA
    Proc Natl Acad Sci U S A; 1968 Feb; 59(2):613-9. PubMed ID: 5238988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.